A strategic CFO with over a decade of experience in biotech and life sciences, specializing in VC and PE-backed ventures. Holding an MA from the University of Cambridge and an FCA qualification, they have deep expertise in fundraising, governance, and operational efficiency, guiding companies to successful growth.
Recently orchestrated the successful acquisition of Dark Blue Therapeutics by Amgen.
Read the full overview →
Experience
7 Years
Current Role
Chief Financial Officer
Job Level
Leadership
Location
Oxford, England, United Kingdom
Personality Overview
How Emma shows up
Cost Conscious
Process Focused
ROI Seeker
They do not like taking risks at all and go for proven options in the end. They are always well-planned and adopt a systematic approach. They are heavily focused on quality and prefer doing things the right way, even if it takes time.
Priorities
Topics Emma cares about
Biotech Finance
Manages the full financial spectrum for life science companies, focusing on financial strategy, fundraising, and scalable operations to support innovative ventures.
Company Acquisitions
Recently demonstrated expertise by leading Dark Blue Therapeutics through a successful acquisition by Amgen, and is certified in advising on business disposals.
+5 more topicsLogin to view topics
Career
Work history
3-2023
Chief Financial Officer
Dark Blue Therapeutics
2-2017 - 2-2023
Fractional CFO and FD consultancy
Elsfa Limited
8-2020 - 7-2021
Interim Finance Director
Cellinta Limited
5-2019 - 2-2021
Interim Financial Controller
Macrophox Limited
9-2018 - 8-2019
Interim Head of FP&A
The Private Infrastructure Development Group
In the press
Media appearances
Amgen Acquires Dark Blue Therapeutics, Bolstering Oncology Pipeline. Featured in BioSpace
Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.
More profiles
Discover additional public profiles from our index.